BridgeBio Oncology Therapeutics, Inc. BBOT
Set alert
2.39 USD +0.08 +3.46%
As of Nov 3, 11:38 AM ET
2.29 Day range 2.40
2.29 52-week range 14.87
- YTD
- -80.91%
- 1 year
- -80.55%
- Open
- 2.37
- Prev close
- 2.31
- Mkt cap
- 191.62M
- Vol
- 186.84K
- Avg vol
- 545.02K
- EPS
- -0.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.29
- High
- 2.40
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 4.43
- Inst. own
- 52.88%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 11.45
- 200-d avg
- 10.84
- 1y target
- 24.20
6M chart
Signals (28)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| RSI: Oversold | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 3 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jul 14, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 25, 2026 | 4 months ago |
Newest 20 of 28.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 24.20 +912.6% upside
Now 2.39
- Target (low)
- 21.00
- Target (mean)
- 24.20
- Target (high)
- 27.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 6
- 2 months ago 6
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.416 | -0.53 – -0.35 | 0.00 | 0.0% | 0 | 0.0% | 5 |
| Next quarter | -0.43 | -0.49 – -0.36 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Current year | -2.23 | -3.18 – -1.43 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Next year | -2.13 | -3.14 – -1.45 | -2.23 | +4.4% | 0 | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 17, 2025 | Leerink Partners | Initiated | — | Outperform |
| Sep 15, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| Sep 4, 2025 | Oppenheimer | Initiated | — | Outperform |
| Aug 18, 2025 | Wedbush | Initiated | — | Outperform |